The Traderszone Network

Published in TZ Latest News 24 August, 2014 by The TZ Newswire Staff

Roche to buy U.S. biotech firm InterMune for $8.3 billion

LONDON/ZURICH (Reuters) – Roche Holding AG (ROG.VX) has agreed to buy U.S. The Swiss drugmaker said on Sunday it would pay $74.00 a share through a tender offer for InterMune, representing a premium of 38 percent to the closing price on Aug. 22. The sale of InterMune will not come as a huge surprise to investors as people familiar with the matter said on Aug. 13 that InterMune was working with financial advisers to evaluate strategic options, due to takeover interest from big drugmakers.

read more